Dr. Khozin is an oncologist and physician-scientist, currently serving as Chief Executive Officer of CancerLinQ, a company focused on advancing cancer care quality and research. Previously, he was Global Head of Data Strategy and Data Science Innovation at J&J, leading a worldwide multidisciplinary team charged with the design and implementation of pioneering data science solutions to support the development of innovative medicines. Before joining J&J, Dr. Khozin led FDA Oncology Center of Excellence’s bioinformatics, regulatory science, and clinical trial innovation efforts and was the founding Executive Director of Information Exchange and Data Transformation (INFORMED), the FDA’s first data science and technology incubator that played a pivotal role in the agency’s technology modernization efforts. Before his tenure in federal government, Dr. Khozin was the cofounder of Hello Health, a company focused on developing integrated telemedicine, point-of-care data visualization, and advanced analytical systems for optimizing patient care and clinical research.
AI Roadmap: Opportunities and Challenges
This session outlines current challenges and opportunities related to the use of AI to advance therapeutic development and care delivery, with a special focus on medical imaging.
Patrick Loerch has over 20 years of experience in data sciences, real world evidence and genomics research spanning all phases of R&D within the pharmaceutical industry. Dr Loerch currently serves as Senior Vice President, Clinical Data Sciences at Gilead Sciences. In addition to oversight of the Biometrics, Clinical Bioinformatics and Real World Evidence organizations, Dr. Loerch is accountable for the build out and integration of Enterprise Data Sciences capabilities to accelerate the discovery, development and delivery of new medicines. Dr. Loerch’s prior roles include leadership positions at Johnson & Johnson, Celgene and Merck. He began his career at Rosetta Inpharmatics, a genomics start-up in Seattle, WA that was later acquired by Merck. Dr. Loerch received his PhD in Biostatistics from the Harvard University and his BS in Biochemistry from Washington State University.
Investor & patients' advocate in systems biology, precision neuroscience. Served on steering committee of the MIT/UCSB Alzheimer’s X initiative, and is on the financing structure committee of the American Medical Association/One Mind Healthy Brain Global Initiative; the Board of Directors of the Global Virus Initiative and the corporate advisory Board of Cancer Expert Now. Adviser to CEO of CancerLinq. Dan is a multi-asset class investor, lawyer and social entrepreneur whose 35-year career has been defined by purposeful engagement as an adviser and investor in important global developments, most recently through his $3.5 Billion Xerion Hedge Funds.
Dr. Nigam Shah is Professor of Medicine (Biomedical Informatics) at Stanford University, and serves as the Associate CIO for Data Science for Stanford Health Care. Dr. Shah's research focuses on bringing machine learning to clinical use safely, ethically and cost-effectively. Dr. Shah was elected into the American College of Medical Informatics (ACMI) in 2015 and was inducted into the American Society for Clinical Investigation (ASCI) in 2016. He holds an MBBS from Baroda Medical College, India, a PhD from Penn State University and completed postdoctoral training at Stanford University.